The prefilled, patient-ready-to-use system is said to support delivery of high-viscosity biologics of up to 50 centipoise.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable ...

Becton Dickinson (BDX) recently announced the initiation of a pharma-sponsored clinical trial featuring their BD Libertas Wearable Injector, alongside an affirmed quarterly dividend and leadership ...

Franklin Lakes, New Jersey Thursday, July 24, 2025, 14:00 Hrs [IST] ...

Becton Dickinson (BDX) announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for ...

President Donald Trump is temporarily exempting medical sterilization facilities that use the colorless gas ethylene oxide ...

The selection of BD LibertasTM Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clini ...

This year, three companies operating four plants in metro-Atlanta applied for an exemption to the new rule: Becton Dickinson ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

In-Vitro Diagnostics Market 2025 IVD market set to grow at 5.0% CAGR to 2032, fueled by chronic disease demand, tech advances, and billion- ...

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are ...